Oscar Gershanik
Oscar Gershanik
Institute of Neuroscience-Favaloro Foundation
Dirección de correo verificada de ffavaloro.org - Página principal
Título
Citado por
Citado por
Año
Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine
M Rubinstein, TJ Phillips, JR Bunzow, TL Falzone, G Dziewczapolski, ...
Cell 90 (6), 991-1001, 1997
5581997
Levodopa in the treatment of Parkinson's disease: current controversies
CW Olanow, Y Agid, Y Mizuno, A Albanese, U Bonucelli, P Damier, ...
Movement disorders 19 (9), 997-1005, 2004
4582004
Early treatment of Parkinson’s disease with cabergoline delays the onset of motor complications
UK Rinne, F Bracco, C Chouza, E Dupont, O Gershanik, JFM Masso, ...
Drugs 55 (1), 23-30, 1998
4221998
Postural deformities in Parkinson's disease
KM Doherty, BP van de Warrenburg, MC Peralta, L Silveira-Moriyama, ...
The Lancet Neurology 10 (6), 538-549, 2011
3902011
Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions
MG Murer, G Dziewczapolski, LB Menalled, MC García, Y Agid, ...
Annals of Neurology: Official Journal of the American Neurological …, 1998
2641998
Levodopa‐induced dyskinesias in Parkinson's disease: clinical and pharmacological classification
MR Luquin, O Scipioni, J Vaamonde, O Gershanik, JA Obeso
Movement disorders: official journal of the Movement Disorder Society 7 (2 …, 1992
2441992
Behavioral correlations of dopamine receptor activation
O Gershanik, RE Heikkila, RC Duvoisin
Neurology 33 (11), 1489-1489, 1983
2171983
The long-acting dopamine receptor agonist cabergoline in early Parkinson’s disease
F Bracco, A Battaglia, C Chouza, E Dupont, O Gershanik, JFM Masso, ...
CNS drugs 18 (11), 733-746, 2004
1632004
Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa
UK Rinne, F Bracco, C Chouza, E Dupont, O Gershanik, JFM Masso, ...
Neurology 48 (2), 363-368, 1997
1591997
Action-verb processing in Parkinson’s disease: new pathways for motor–language coupling
JF Cardona, O Gershanik, C Gelormini-Lezama, AL Houck, S Cardona, ...
Brain Structure and Function 218 (6), 1355-1373, 2013
1522013
Motor-language coupling: direct evidence from early Parkinson’s disease and intracranial cortical recordings
A Ibáñez, JF Cardona, YV Dos Santos, A Blenkmann, P Aravena, M Roca, ...
cortex 49 (4), 968-984, 2013
1502013
Expanded and independent validation of the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)
P Martinez-Martin, C Rodriguez-Blazquez, M Alvarez-Sanchez, T Arakaki, ...
Journal of neurology 260 (1), 228-236, 2013
1462013
Levodopa in the treatment of Parkinson's disease: a consensus meeting
Y Agid, E Ahlskog, A Albanese, D Calne, T Chase, J De Yebenes, ...
Movement disorders 14 (6), 911-913, 1999
1221999
Impairments in social cognition in early medicated and unmedicated Parkinson disease
M Roca, T Torralva, E Gleichgerrcht, A Chade, GG Arévalo, O Gershanik, ...
Cognitive and Behavioral Neurology 23 (3), 152-158, 2010
1182010
Neuropsychological disturbances in hemiparkinson's disease
S Starkstein, R Leiguarda, O Gershanik, M Berthier
Neurology 37 (11), 1762-1762, 1987
1111987
Polysomnographic measures in Parkinson's disease: a comparison between patients with and without REM sleep disturbances.
TC Wetter, C Trenkwalder, O Gershanik, B Högl
Wiener Klinische Wochenschrift 113 (7-8), 249-253, 2001
1022001
Assessing the non‐motor symptoms of Parkinson's disease: MDS‐UPDRS and NMS Scale
P Martinez‐Martin, KR Chaudhuri, JM Rojo‐Abuin, ...
European Journal of Neurology 22 (1), 37-43, 2015
992015
A clinical, pharmacologic, and polysomnographic study of sleep benefit in Parkinson's disease
BE Höl, G Gomez-Arevalo, S Garcia, O Scipioni, M Rubio, M Blanco, ...
Neurology 50 (5), 1332-1339, 1998
971998
Clinical and pharmacological differences in early‐versus late‐onset Parkinson's disease
GG Arevalo, R Jorge, S Garcia, O Scipioni, O Gershanik
Movement disorders: official journal of the Movement Disorder Society 12 (3 …, 1997
831997
How embodied is action language? Neurological evidence from motor diseases
JF Cardona, L Kargieman, V Sinay, O Gershanik, C Gelormini, L Amoruso, ...
Cognition 131 (2), 311-322, 2014
782014
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20